Preclinical and Toxicology Studies of BRD5529, a Selective Inhibitor of CARD9 [0.03%]
BRD5529（CARD9选择性抑制剂）的药理和毒理研究
Theodore J Kottom,Kyle Schaefbauer,Eva M Carmona et al.
Theodore J Kottom et al.
Background: The caspase recruitment domain-containing protein 9 (CARD9) inhibitor BRD5529 has been shown to be an effective in vitro inhibitor of Pneumocystis β-glucan-induced proinflammatory signaling, suggesting its vi...
Evaluation of the Pharmacokinetics and Safety of AMG 986 Tablet and Capsule Formulations in Healthy Adult Subjects: A Phase I, Open-Label, Randomized Study [0.03%]
一项评价AMG 986片剂和胶囊剂型在健康成人受试者中的药代动力学及安全性的I期开放标签、随机试验
Ashit Trivedi,Y-H Kiang,Robert E Saw et al.
Ashit Trivedi et al.
Background and objective: AMG 986 is a first-in-class, novel apelin receptor small molecule agonist initially developed for the treatment of heart failure. The current phase I study was conducted to evaluate the pharmacok...
Clinical Trial
Drugs in R&D. 2022 Jun;22(2):147-154. DOI:10.1007/s40268-022-00388-1 2022
Pharmacokinetics and Safety of Ferric Pyrophosphate Citrate in Chinese Subjects with and without Hemodialysis-Dependent Stage 5 Chronic Kidney Disease [0.03%]
含铁焦磷酸盐在中国5期慢性肾脏病患者（包括血液透析依赖性和非血液透析依赖性）中的药代动力学和安全性研究
Liangying Gan,Panpan Xie,Yan Tan et al.
Liangying Gan et al.
Background and objective: Anemia caused by iron depletion is common in patients with hemodialysis-dependent stage 5 chronic kidney disease (CKD-5HD) patients. To maintain the iron levels, external administration of iron i...
Randomized Controlled Trial
Drugs in R&D. 2022 Jun;22(2):119-129. DOI:10.1007/s40268-022-00384-5 2022
First-in-Human Phase I Study of the Novel Injectable Calcimimetic Agent Upacicalcet in Healthy Adult Japanese Participants [0.03%]
新型可注射钙敏化剂Upacicalcet在健康成人日本受试者中的首次人体I期临床试验
Fumihiko Koiwa,Rie Yazawa,Masafumi Fukagawa et al.
Fumihiko Koiwa et al.
Background and objective: Upacicalcet sodium hydrate is a novel small-molecule calcimimetic and has potential as a therapeutic agent for secondary hyperparathyroidism. We assessed the pharmacokinetics, pharmacodynamics, s...
Clinical Trial
Drugs in R&D. 2022 Jun;22(2):131-140. DOI:10.1007/s40268-022-00385-4 2022
A Phase I, Open-label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of AMG 986 in Healthy Japanese Subjects [0.03%]
一项在健康日本受试者中评估AMG 986单次给药后的药代动力学、安全性和耐受性的I期开放标签研究
Ashit Trivedi,Omar Mather,Silvia Vega et al.
Ashit Trivedi et al.
Background and objective: AMG 986 is a first-in-class, novel apelin receptor small molecule agonist initially developed as a treatment for patients with heart failure (HF). Previously, a first-in-human study of AMG 986 wa...
Matthew W McCarthy
Matthew W McCarthy
Lysins are bacteriophage-derived enzymes that degrade essential components of bacteria. Exebacase (Lysin CF-301) is an attractive antimicrobial agent because it demonstrates rapid bacteriolytic activity against staphylococcal species, inclu...
Safety, Pharmacokinetic, and Pharmacodynamic Study of a Sublingual Formula for the Treatment of Vasovagal Syncope [0.03%]
舌下给药治疗血管迷走性晕厥的耐受性和药代动力学、药效学研究
Paul Hutson,Regis Guieu,Jean-Claude Deharo et al.
Paul Hutson et al.
Background: Vasovagal syncope is a common cause of syncope which, if recurrent, can have multiple negative consequences such as injury and occupational disability. Various medications can be used to decrease the recurrenc...
Clinical Trial
Drugs in R&D. 2022 Mar;22(1):61-70. DOI:10.1007/s40268-021-00378-9 2022
An Evaluation of the Pharmacokinetics, Safety, and Tolerability of Aclidinium/Formoterol Fixed-Dose Combination Administered in Chinese Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease [0.03%]
aclidinium/formoterol固定剂量复方在中重度慢性阻塞性肺疾病中国患者中的药代动力学、安全性和耐受性评估研究
Hong Zhang,Sami Z Daoud,Michael S Gillen et al.
Hong Zhang et al.
Background and objectives: The aim of this study was to evaluate the pharmacokinetics, safety, and tolerability of aclidinium bromide/formoterol fumarate in patients from China with moderate-to-severe chronic obstructive ...
Clinical Trial
Drugs in R&D. 2022 Mar;22(1):35-42. DOI:10.1007/s40268-021-00374-z 2022
NLRP3 Inhibitor Tranilast Attenuates Gestational Diabetes Mellitus in a Genetic Mouse Model [0.03%]
NLRP3抑制剂曲尼司特可以缓解遗传小鼠模型妊娠期糖尿病
Jing Cao,Qian Peng
Jing Cao
Background and objective: This study was designed to explore the protective effects of a clinically available NLR family Pyrin domain-containing receptor 3 (NLRP3) inhibitor, tranilast, in gestational diabetes mellitus (G...
In Vitro Stability and Recovery Studies of Pimavanserin in Water and in Different Vehicles Orally Administered [0.03%]
匹美 vanserin 在水和不同口服介质中的体外稳定性及回收率研究
Allan David Bokser,Yvonne Holmes Adegbenle,Vesna Stoisavljevic et al.
Allan David Bokser et al.
Background and objective: Swallowing difficulties (i.e., dysphagia) occur in up to 40% of the adult general population, particularly among the elderly prescribed solid oral dosage forms. Pimavanserin is approved for the t...